Tags: Drug.

Idelalisib (codenamed GS-1101 or CAL-101) is a drug under investigation for the treatment of chronic lymphocytic leukaemia. It is in Phase III clinical trials testing drug combinations with rituximab and/or bendamustine as of 2013. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically it blocks P110δ the delta isoform of the enzyme phosphoinositide 3-kinase.

Idelalisib_skeletal.svg
ATC prefix
None
IUPAC name
5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
PubChem
11625818

Loading...

This page contains content from the copyrighted Wikipedia article "Idelalisib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.